RP-0320

RP-0320 is a **preclinical small-molecule oncology candidate** from **Penrose TherapeuTx** and the lead program from the company’s **mitochondrial modifying agent** platform. Penrose has described this platform as creating a **selective mitochondrial vulnerability** in cancer cells that drives **metabolic collapse** and ultimately **necrotic cell death**, with intended applicability across both hematologic and solid tumors. Publicly available information links RP-0320 to development in **acute myeloid leukemia**, **breast cancer**, and **colorectal cancer**, but the specific molecular target or binding partner has not been clearly disclosed in the available source material.